Saatci Ali Osman, Selver Ozlem Barut, Seymenoglu Goktug, Yaman Aylin
Department of Ophthalmology, Dokuz Eylul University, Manisa, Turkey.
Case Rep Ophthalmol. 2013 Mar 25;4(1):53-8. doi: 10.1159/000350544. Print 2013 Jan.
To report the efficacy of intravitreal dexamethasone implant in a patient with retinitis pigmentosa and bilateral cystoid macular edema unresponsive to topical carbonic anhydrase inhibitors.
A 36-year-old man with bilateral cystoid macular edema associated with retinitis pigmentosa that was unresponsive to topical carbonic anhydrase inhibitors underwent bilateral 0.7-mg intravitreal dexamethasone implants two weeks apart. Spectral domain optical coherence tomography revealed resolution of macular edema one week following each injection in both eyes and his visual acuity improved. However, macular edema recurred two months later in OS and three months later in OD. Second implant was considered for both eyes. No implant-related complication was experienced during the follow-up of seven months.
Inflammatory process seems to play a role in retinitis pigmentosa. Intravitreal dexamethasone implant may offer retina specialists a therapeutic option especially in cases unresponsive to other treatment regimens in eyes with retinitis pigmentosa-related macular edema.
报告玻璃体内注射地塞米松植入物治疗一名患有色素性视网膜炎及双侧黄斑囊样水肿且对局部碳酸酐酶抑制剂无反应患者的疗效。
一名36岁男性,患有与色素性视网膜炎相关的双侧黄斑囊样水肿,对局部碳酸酐酶抑制剂无反应,在相隔两周的时间里双眼分别接受了0.7毫克的玻璃体内地塞米松植入物注射。频域光学相干断层扫描显示,双眼每次注射后一周黄斑水肿消退,视力提高。然而,两个月后左眼黄斑水肿复发,三个月后右眼黄斑水肿复发。考虑对双眼进行第二次植入。在七个月的随访期间未出现与植入物相关的并发症。
炎症过程似乎在色素性视网膜炎中起作用。玻璃体内注射地塞米松植入物可能为视网膜专科医生提供一种治疗选择,特别是对于患有色素性视网膜炎相关黄斑水肿且对其他治疗方案无反应的病例。